“Strategic market positioning” needed for Ebglyss to rival Dupixent in atopic dermatitis – Pharmaceutical Technology
The atopic dermatitis US market size was estimated to be worth $7.1bn in 2023. Image credit: Shutterstock/ Katarzyna Hurova. Eli Lilly’s Ebglyss (lebrikizumab) will require